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Perinatal asphyxia is a major cause of death and disability in 
children. Therapeutic hypothermia (TH) has become a standard 
of care for newborn infants who have sustained hypoxic ischaemic 
encephalopathy (HIE) due to perinatal asphyxia. There is compelling 
evidence to support this approach. A Cochrane systematic review of 
11 prospective randomised controlled trials including 1 505 newborns 
showed that TH started within 6 hours of birth in infants with HIE 
significantly decreased mortality and neurodevelopmental disability 
in survivors.[1] Several academic hospitals in South Africa (SA) 
have been cooling newborns with HIE since 2008, with favourable 
outcomes.[2] However, Thayyil et al.[3] recently published results of 
the HELIX trial, a large, well-designed, multicentre randomised 
controlled trial conducted in India, Sri Lanka and Bangladesh, which 
showed that TH did not decrease neurodevelopmental handicap and 
actually increased mortality. The authors of this study concluded that 
TH should not be offered in the treatment of neonatal encephalopathy 
in low- and middle-income countries (LMICs). The HELIX study 
was conducted using servo-controlled cooling equipment in hospitals 
with intensive care facilities, so the increased mortality could not be 
explained by inferior equipment or lack of intensive care facilities. 
The HELIX study group subsequently wrote a commentary in the 
Indian Journal of Pediatrics stating that it is time to stop offering TH 
for neonatal encephalopathy in LMICS, owing to the lack of benefit 
and increased mortality.[4] These authors argue that the body of 
research supporting the use of TH was performed in high-income 
countries (HICs) and that the HELIX study results conclusively show 
that it is of no benefit in LMICs.
We believe for several reasons that it is inappropriate for the 
HELIX authors to make a generalisation that TH should not be used 
in LMICs based on the findings of their study. Firstly, it is not clear 
that the patients enrolled in the HELIX trial had sustained acute 
intrapartum hypoxia, for which TH has been shown to be effective. 
Sentinel events suggestive of intrapartum hypoxia and fetal heart 
rate decelerations were only reported in 11% and 6% of enrolled 
patients, respectively. Only 3% of mothers were reported to have had 
a prolonged second stage, and 1% had obstructed labour. There was 
no report of neonatal blood gases within the first hour after delivery, 
and only 11% had cord blood gases documented. These numbers are 
much lower than those that have been reported in studies that have 
shown TH to be effective. Secondly, it would appear that the HELIX 
group enrolled neonates who were critically ill compared with other 
studies, with 80% and 70% of their patients requiring inotropes 
and mechanical ventilation, respectively, compared with 34% and 
17% from an SA study. This could explain their high mortality of 
36% compared with mortality of 14% in SA studies.[5] Thirdly, basal 
ganglia injury on brain magnetic resonance imaging, which is an 
injury related to an acute intrapartum hypoxic event, was only seen 
in 25% of neonates in the HELIX trial compared with 48 - 79% in 
studies in HICs where TH was reported to be effective.[6,7] Lastly, the 
results from TH trials in HICs reported a 47% reduction in disabling 
cerebral palsy in neonates who received TH compared with those 
who received the standard of care.
We have been offering TH in neonates with HIE in SA for more 
than a decade, with apparently reasonable outcomes, with in-hospital 
mortality of 13 - 14%[2,5] and normal neurological outcome or mild 
impairment in 82% at 12 months[2] and 68% at 18 - 24 months.[8] 
We therefore have a major concern with this ‘all or none’ approach 
recommended by the HELIX authors. In addition, contrary to what 
the HELIX authors have recommended, a recent meta-analysis on 
TH for asphyxiated neonates with encephalopathy recommends 
that TH should be offered as part of the standard of care, as the 
reduction in mortality was found to be greatest in LMICs.[9] Aneja 
and Sharma[10] propose a more measured approach and acknowledge 
the strengths of the HELIX study, but also discuss several possible 
reasons for the unexpected poor outcomes with TH, rather than the 
location being LMICs per se. In addition to the reasons highlighted 
above, these include a high number of small-for-gestational-age and 
low-birthweight infants in the HELIX trial, a significant number of 
infants born outside hospital, and a large proportion of infants with 
seizures at the time of enrolment. In addition, the HELIX authors 
themselves suggest that population factors may account for the 
different response to TH in their study.[3]
We therefore suggest a moderated response to the HELIX trial 
results. We still do not understand everything about perinatal 
asphyxia and HIE, and it is premature to dismiss a potentially 
beneficial therapy based on the results of a single study conducted in 
a population and context very different from our own. As suggested 
by Aneja and Sharma,[10] TH should not be regarded as a standard of 
care, but should be used in referral hospitals and according to strict 
protocols. We need to continue research into HIE and TH to identify 
those infants who will benefit the most from this treatment. The 
Neonatal Encephalopathy with Suspected Encephalopathy (NESHIE) 
study is an ongoing prospective multicentre observational study in 
SA to determine the role of genomics and other factors in HIE. We 
may need to limit TH to certain subgroups of infants. For example, 
it appears that out-born babies may not have as favourable outcomes 
and should therefore possibly be excluded from TH.
Randomised controlled trials (RCTs) are the gold standard for 
evaluating the effectiveness of interventions, but since TH has 
previously been shown to be effective and safe in reducing adverse 
HIE outcomes (in both LMICs and HICs) and we have been offering 
TH for the past 10 years, it has so far not been ethical or appropriate 
to randomise asphyxiated neonates into groups with or without 
TH. Perhaps the HELIX results will allow ethical approval for a 
prospective, multicentre RCT of TH in SA to properly evaluate TH in 
the local context, allowing us to make more informed decisions about 
its ongoing use in our centres. It could also be more generalisable to 
us and our neighbouring countries than perhaps the HELIX trial is.
In conclusion, although the results of the HELIX trial are 
concerning and highlight the need for caution, we do not support 
the notion of abandoning the use of TH in SA. Instead, we agree that 
TH should be used according to strict protocols in referral hospitals. 
We also support ongoing research into both HIE and TH in our local 
context, and would welcome the opportunity to perform an RCT.
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